NAD+

Steady

NAD+ appears in 3,067 indexed publications going back to 2017, including 337 in the past twelve months. 204 registered trials appear on ClinicalTrials.gov, 2 with Australian sites.

3,067
Indexed publications
337
Past 12 months, against 282 the year before
204
Registered clinical trials
13,685
Monthly readers on Wikipedia, down 8%

On This Figure
NAD+ is a coenzyme present in every living cell, so this figure describes an entire field of metabolic research rather than one compound.

Research Activity

Publication history

How much work has been indexed each year, from Europe PMC. Momentum is measured over a trailing twelve months rather than calendar years, so a partial current year never reads as a decline.

20152026

Publications per year. The final bar is the current year, still in progress.

Indexed publications per year
20150
20160
20173
20186
201918
202034
202159
2022109
2023130
2024199
2025232
2026210
Public Attention

Who is looking it up

Monthly readers of the NAD+ article on English Wikipedia. An independent measure of curiosity, which often moves quite differently from the evidence.

2025-082026-07
Clinical Trials

The registered pipeline

Early Phase 1
3
Phase 1
6
Phase 2
7
Phase 3
1
Phase 4
0

2 trials have a registered Australian site.

Phase distribution across the most recently updated registered trials.

References

Most recent work

The newest indexed records mentioning NAD+, listed by publication date. Titles are shown as published and link to their source. Inclusion here is a record of what exists, not a judgement of what it shows.

  1. 2026-06-27·Bioactive materials

    A senescent metabolism-modulating hierarchical scaffold restores NAD<sup>+</sup> homeostasis and redox balance for aged bone repair

    Jiang J, Chen J, Wang X et al.

  2. 2026-02-12·Pharmaceutical science advances

    NAD<sup>+</sup> precursor supplementation reverses CD36-mediated lipid accumulation and ferroptosis to restore antitumor function of NK cells in DLBCL

    Shi L, Huang X, Han X et al.

  3. 2026-04-16·Renal failure

    Targeting the NAD<sup>+</sup>-SIRT3 axis to mitigate metabolic memory in diabetic kidney disease

    Zhang Y, Wang Y, Qiao Y et al.

  4. 2026-03-10·Gut microbes

    <i>Bacteroides</i>-associated NAD⁺ depletion correlates with exacerbated radiation-induced colorectal injury and impaired mucosal proliferative capacity

    Huang J, Qin Q, Li X et al.

  5. 2026-04-27·Biomaterials

    Local inhibition of glaucomatous mitochondrial dysfunction using an engineered annular sector microneedle

    Huang B, Xu W, Qiu X et al.

  6. 2026-06-24·Experimental neurology

    Programmed axon degeneration gene variants in human disease

    Hopkins EL, Williams PA. et al.

  7. 2025-10-18·Genes & diseases

    The therapeutic effect of nicotinamide riboside chloride on ameliorating alcohol-induced neuronal damage with a focus on mitochondrial unfolded protein response and mitophagy

    Wang J, Wang J, Xie W et al.

  8. 2026-05-05·Theriogenology

    Nicotinamide mononucleotide (NMN) improves the ovarian microenvironment associated with oocyte quality by increasing estrogen signaling, reprogramming ovarian metabolism, reducing oxidative stress, and inhibiting apoptosis in the spotted scat (Scatophagus argus)

    Luo J, Wang S, Lin X et al.

In the Catalogue

NAD+ available from Polaris Research

Supplied as research materials for laboratory use. Free express delivery Australia wide.

Sources

Publication data from Europe PMC. Clinical trial data from ClinicalTrials.gov, U.S. National Library of Medicine. Public attention from Wikimedia pageview data. Evidence grades from reptides.co. We report counts and dates from these sources and link every record to its origin, we do not summarise findings. Last synced 2026-08-02.